Whalesbook
The Current Reimbursement Squeeze
The current CGHS reimbursement policy, capping hospital payments at 70% of the Maximum Retail Price (MRP) for essential high-cost oncology medicines, has created a difficult financial situation for private healthcare providers. This shortfall forces hospitals to absorb the remaining 30% deficit, a burden that is rapidly becoming unsustainable given the already thin profit margins, often ranging between 10-15% for these specialized treatments. The Association of Healthcare Providers (India) (AHPI) has warned the health ministry about this growing crisis, identifying nine specific patented immunotherapy drugs that are now increasingly out of reach for CGHS beneficiaries.
The Price-Cap Paradox
The core problem is the large difference between the cost of patented immunotherapy drugs and the government's payment limit. For instance, Keytruda, a vital immunotherapy drug, costs approximately ₹1.5 lakh per 100 mg vial in India, with monthly treatment expenses potentially exceeding ₹3 lakh. Under the CGHS policy, hospitals receive only 70% of the MRP, leaving them to cover the remaining 30% out-of-pocket. This deficit, when applied to the substantial cost of these advanced treatments, creates significant financial strain. The Indian oncology drug market, while projected for substantial growth driven by rising cancer incidence and demand for advanced therapies, faces a major hurdle in payment systems, which contribute over 60% to patient out-of-pocket expenditure.
Operational Roadblocks and Unviable Pathways
Hospitals find the current reimbursement pathways difficult due to practical and legal issues. One option requires hospitals to bill CGHS at the full MRP but only receive 70% of the amount, directly impacting their bottom line. Many hospitals procure these patented drugs through complex bulk contracts with multinational pharmaceutical companies, agreements that often prohibit disclosing negotiated prices to third parties. Submitting purchase invoices to CGHS could therefore expose hospitals to breach of contract claims, potentially leading to supply disruptions from drug manufacturers. Alternative routes, such as asking patients to procure their own medicines, are medically risky due to the strict temperature control needed for storage and the difficulty patients face in ensuring the drugs are genuine and properly stored. Furthermore, the CGHS's own supply chain has historically suffered from reported delays and shortages, leading to disrupted treatment schedules and poorer patient results.
The Financial Squeeze on Private Providers
Government health schemes, including CGHS, typically account for a large part of revenue for major private hospital networks, estimated at 20-25%. However, this share is under pressure. Analysts predict that revenue from these schemes could shrink by an additional 3-5% by the first quarter of fiscal year 2027 due to hospitals limiting their involvement or reducing available beds. Major hospital chains have reported substantial financial impacts; Max Healthcare, for example, noted a ₹200 crore revenue impact from its CGHS engagement. These financial adjustments are seen in company market values, with major hospital chains like Max Healthcare holding a market capitalization of approximately ₹98,871 crore (P/E ~140.81) and Apollo Hospitals at ₹111,253 crore (P/E ~60.93) as of early May 2026. However, the high P/E ratios for some, like Fortis Healthcare at ₹71,687 crore (P/E ~439.54) and HealthCare Global Enterprises (HCG) at ₹8,612 crore (P/E ~429.50), may indicate investor caution about profitability due to these scheme problems.
Policy Stagnation and Revisions
CGHS reimbursement rates have historically been a recurring issue. Prior to a major update in October 2025, rates for many procedures had remained unchanged since 2014. The October 2025 revision introduced a tiered, quality-linked pricing structure, correlating reimbursement with hospital accreditation, city tier, and ward entitlement. This reform aimed to boost financial viability and improve accessibility. While these adjustments may offer some relief for certain services, the fundamental issue of a 70% MRP cap on specific high-cost patented drugs like those used in advanced cancer therapy remains a major obstacle. AHPI has consistently asked for reimbursement at the full MRP for such essential medicines, a demand that highlights the ongoing policy shortfall.
Provider Challenges and Risks
Hospital Experiences and Dues
Hospitals regularly face these challenges in navigating government reimbursement schemes. Major hospital groups, including Max Healthcare, Fortis Healthcare, and HealthCare Global Enterprises, have publicly acknowledged significant revenue hits and financial difficulties because of their involvement in schemes like CGHS. AHPI has previously pointed to over ₹500 crore in overdue payments to more than 60 private hospitals, along with long reimbursement delays that hadn't been updated since 2014.
Impact on Treatment Access
This policy environment creates a fundamental weakness for private providers who rely on government schemes for a large part of revenue. Unlike private insurance or self-pay patients who bring in more profit, the CGHS reimbursement cap for life-saving patented drugs puts hospitals in a difficult financial spot, possibly discouraging them from offering these advanced treatments. While the overall Indian oncology market is set to grow, the lack of sufficient payment plans for cancer treatments creates a major barrier to access.
Key Risks to Patient Care and Operations
The primary risk is severely limited patient access to essential, life-saving immunotherapy drugs because of cost and payment shortfalls. Hospitals face the risk of breaking contracts with drug makers if they disclose prices against rules. This could lead to disruptions in the supply of these crucial medicines. Furthermore, the continued financial pressure on hospitals, shown by high price-to-earnings ratios for some large chains, could harm their long-term stability and ability to invest in new technology, affecting overall healthcare quality. This policy situation risks undermining the aim of expanding access to advanced cancer treatments.
Future Outlook
The Association of Healthcare Providers (India) is asking CGHS to review its payment policy, pushing for full MRP payments for these critical patented oncology drugs to ensure financial sustainability for hospitals and continued access for patients. While the Indian oncology market is poised for expansion, driven by rising cancer incidence and innovation in therapies, how well these treatments work will heavily depend on the government matching payment policies to the real costs of advanced, life-saving medications.